Guggenheim Initiates Coverage On Eloxx Pharma with Buy Rating, Announces Price Target of $43
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsInitiationPrice Target
Guggenheim analyst Vamil Divan initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Buy rating and announces Price Target of $43.
Guggenheim analyst Vamil Divan initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Buy rating and announces Price Target of $43.